JR...Once Lr-Et-EPA comes to market, the court case against Hickma for infringing on Amarin's CVD patent on Vascepa becomes far less important to Amarin ...and Amarin might then be inclined to accept a decent monetary settlement of the case from Hikma as compensation for their severe loss of income.
Market Data 
Markets 
